Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1976-7-6
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0069-0112
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
59
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1155-6
|
pubmed:dateRevised |
2008-2-20
|
pubmed:meshHeading |
pubmed-meshheading:769955-Burkitt Lymphoma,
pubmed-meshheading:769955-Clinical Trials as Topic,
pubmed-meshheading:769955-Humans,
pubmed-meshheading:769955-Lomustine,
pubmed-meshheading:769955-Nitrosourea Compounds,
pubmed-meshheading:769955-Remission, Spontaneous,
pubmed-meshheading:769955-Time Factors
|
pubmed:articleTitle |
Evaluation of CCNU (NSC-79037) used for the prevention of CNS involvement in Burkitt's lymphoma.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|